Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07354477 · ClinicalTrials.gov registry record · Phase 2
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
A Phase 2 study of Open Angle Glaucoma (OAG) and Non-proliferative Diabetic Retinopathy (NPDR), sponsored by Qlaris Bio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT07354477 is a Phase 2 study of Open Angle Glaucoma (OAG) and Non-proliferative Diabetic Retinopathy (NPDR) that is actively recruiting participants, run by Qlaris Bio. The registered enrollment target is 14 participants, below the 66-participant average among 5 other Open Angle Glaucoma (OAG) trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07354477, a Phase 2 study of Open Angle Glaucoma (OAG) and Non-proliferative Diabetic Retinopathy (NPDR), is actively recruiting participants, sponsored by Qlaris Bio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG
Conditions Studied
Interventions
- DRUG QLS-111 Ophthalmic Solution (0.015%)
- DRUG QLS-111 Ophthalmic Solution (0.075%)
Study Locations (1)
California
- Stanford University, Dept. of Ophthalmology - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2026-02-20 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07354477
The ClinicalTrials.gov registry entry for NCT07354477 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 66-participant average among 5 other Open Angle Glaucoma (OAG) trials with a reported enrollment target (79% lower). The listed sponsor is Qlaris Bio, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Open Angle Glaucoma (OAG) appearing as the primary indexed condition, and to 2 interventions - of which QLS-111 Ophthalmic Solution (0.015%) is the first listed.
NCT07354477 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07354477 about?
NCT07354477 is a clinical study titled "Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation". Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG
What is the current status of trial NCT07354477?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2026-02-20. Estimated completion is 2026-06.
What conditions does trial NCT07354477 study?
This clinical trial studies the following conditions: Open Angle Glaucoma (OAG), Non-proliferative Diabetic Retinopathy (NPDR), Normal Tension Glaucoma (NTG).
What interventions are being tested in trial NCT07354477?
The interventions under investigation include: QLS-111 Ophthalmic Solution (0.015%) (DRUG), QLS-111 Ophthalmic Solution (0.075%) (DRUG).
Who is sponsoring clinical trial NCT07354477?
This trial is sponsored by Qlaris Bio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07354477 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Open Angle Glaucoma (OAG)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Travoprost Five Day Posology Study
COMPLETED · Phase 2
-
DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma
RECRUITING
-
Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg
RECRUITING
-
Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma
RECRUITING · NA
-
Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)
RECRUITING · Phase 1
Explore more on PlainTrial
Open Angle Glaucoma (OAG)
All registered trials for this condition
Non-proliferative Diabetic Retinopathy (NPDR)
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.